A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

10.1038/s41408-021-00544-x

Saved in:

Bibliographic Details
Main Authors:	Chen, Yunxin, Gopalakrishnan, Sathish Kumar, Ooi, Melissa, Sultana, Rehena, Lim, Li Hui, Grigoropoulos, Nicholas, Ong, Shin Yeu, Xu, Mingge, Chng, Wee Joo, Goh, Yeow Tee, Nagarajan, Chandramouli
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Letter
Language:	English
Published:	SPRINGERNATURE 2021
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology Hematology MULTIPLE-MYELOMA LENALIDOMIDE
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/207736
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Be the first to leave a comment!